Learn / FMK
Every FMK condition
299 diseases, deficiencies, toxicities and drug mechanisms harvested from every FMK deck — the ones sprinkled through a single bullet as much as the ones with their own slide. Pick what you're given and what you have to name, or let it cycle; distractors come from the same category so you have to discriminate (hypoketotic vs. ketotic hypoglycemia, which GSD, which urea-cycle enzyme…). Every answer shows the whole card with the lecture and slide.
Toxin/Drug · FMK 04.4
PCSK9 inhibitors (evolocumab, alirocumab) Acquired / not inherited
Defect / target: PCSK9 (normally binds LDL receptor and targets it for lysosomal degradation)
Mechanism: Blocking PCSK9 lets more LDL receptors recycle to the surface, further lowering LDL; additive to statins in FH.
Presentation: add-on therapy for familial hypercholesterolemia
Labs: ↓↓ LDL (additive)
Learn the mechanism: Cholesterol synthesis →
FMK 04.4 Lipid Digestion, Transport & Storage · slide 21, 29, 30; FMK 05.1 slide 12